Imatinib mesylate is a potent, molecularly targeted therapy against the oncogenic tyrosine
kinase BCR-ABL. Although imatinib mesylate has considerable efficacy against chronic …

The 92-kDa gelatinase (MMP-9) expression is prerequisite for tissue remodeling in physiology
and cancer. However, there are few known regulators of MMP-9 expression. Using an …

Bcr-abl kinase inhibitors have provided proof of principal that targeted therapy holds great
promise for the treatment of cancer. However, despite the success of these agents in treating …

Background The fusion protein BCRABL results in constitutive tyrosine kinase activity. It
also affects downstream targets as well as the subcellular location of the normally tightly …

Chronic myeloid leukemia (CML) is initially driven by the bcr–abl fusion oncoprotein. The
identification of bcr–abl led to the discovery and rapid translation into the clinic of bcr–abl …

B-cell acute lymphoblastic leukemia (ALL) is characterized by accumulation of immature
hematopoietic cells in the bone marrow, a well-established sanctuary site for leukemic cell …

Selenomabs are engineered monoclonal antibodies with one or more translationally incorporated
selenocysteine residues. The unique reactivity of the selenol group of selenocysteine …

Background/Aim: One of the major hurdles in the treatment of breast cancers is the inability
of anti-cancer drugs to eliminate the breast cancer stem cells (BCSCs) population, which …

In this study, we show that conditioned media (CM) generated from bone marrow (BM)-derived
mesenchymal stromal cells lead to BCR-ABL independent STAT3 activation. Activation of …

HYD1 is a D–amino acid peptide that was previously shown to inhibit adhesion of prostate
cancer cells to the extracellular matrix. In this study, we show that in addition to inhibiting …